Direct Compression Tablets with Micronized Active and Dry Binder Systems

Direct compression of N,N'-didodecyl dithiooxamide as a micronized active ingredient imposes stringent control over powder flow and segregation tendency because the parent molecule consists of a dithiooxamide core flanked by two saturated dodecyl chains, reducing aqueous wettability and increasing particle-cohesion forces. In production-scale batches, blending is performed in a 600 L bin blender with an intensifier bar at 12 rpm for 20–30 minutes after geometric preblending of the active with microcrystalline cellulose and pregelatinized starch. The formula addition ratio evaluated for immediate-release tablets ranges from 2.5% w/w to 25.0% w/w of the active, with 0.5%–1.5% w/w magnesium stearate added only in the final 3 minutes to limit shear-induced over-lubrication. Compliance is governed by USP <905> for uniformity of dosage units, USP <711> for dissolution testing with 900 mL of 0.1 N hydrochloric acid containing 0.5% w/v sodium dodecyl sulfate at 50 rpm paddle speed, ICH Q3D for elemental impurities, and 21 CFR 211.165 for release testing. Compression is carried out on a Fette 2090i or Korsch XL 400 rotary press with 10-station tooling, B-tooling, precompression force 2–6 kN, main compression force 8–18 kN, and turret speed 30–80 rpm. Tablet hardness is maintained between 50 N and 110 N, while ejection force is monitored to remain below 800 N to avoid picking and sticking on the lower punch face. The terminal product type is a round, biconvex immediate-release tablet with total mass 100–500 mg, packed in HDPE bottles or blister packs; dissolution lot release is performed using Apparatus 2 at 50 rpm.

What Limits Powder Flow During Encapsulation of Low-Bulk-Density Blends?

In capsule filling operations for the active, lubricant level and particle-size distribution of the dry blend govern weight uniformity because the two dodecyl chains impart a low consolidated bulk density and high static charge retention when pulverized below 15 µm D90. A dosator-type encapsulation machine such as the MG2 Planeta or Bosch GKF 2600 is operated with 2–5 tamping pin stations and pin compression force 50–150 N; the fill weight is targeted at 120–300 mg for size 0 or 1 hard gelatin and HPMC capsules. The active is blended at 2.0% w/w to 20.0% w/w with lactose monohydrate 200 Mesh, pregelatinized starch, and 0.25%–0.75% w/w colloidal silicon dioxide added to reduce electrostatic adhesion to the dosing disc. Granular flow, characterized by a flow function coefficient ffc ≥ 5 using a ring shear tester according to ASTM D6773, is required to maintain weight variation under ±4% for average fill weight below 300 mg, as defined by USP <905>. Analytical compliance includes USP <2040> for disintegration of capsules using water at 37 ± 2 °C, and ICH Q3D for elemental impurity profiling; microbial limits follow USP <1111> for nonsterile products. The downstream production process uses a stepwise blending sequence: active and silicon dioxide are passed through a 30-mesh sieve, then mixed with diluent in a 150 L bin blender at 15 rpm for 15 minutes; lubricant is added and blended for an additional 3 minutes. Terminal product types include immediate-release hard-shell capsules and HPMC vegetarian capsules, with printed identification and no functional coating.

Roller compaction routes are selected when the active exhibits a high aspect ratio or static charging behavior that precludes direct compression at tablet press speeds above 50 rpm. Dry granulation is performed on a Gerteis Mini-Pactor or Alexanderwerk WP 120 roller compactor with gap setting 1.5–3.0 mm, roll force 8–20 kN/cm, and roll speed 2–10 rpm. The formula addition ratio in the pre-blend ranges from 5.0% w/w to 30.0% w/w of the active, with 5–15% w/w microcrystalline cellulose as binder and 1–3% w/w crospovidone as disintegrant added before dry granulation. Ribbon density is controlled between 0.9 g/cm³ and 1.2 g/cm³ by adjusting roll force; ribbons are milled through an oscillating granulator fitted with a 0.8–1.25 mm screen, and granules larger than 850 µm are recycled at a maximum 25% ratio to avoid excessive fines. The granulation is lubricated with 0.5%–1.0% w/w sodium stearyl fumarate and compressed on a 16-station rotary tablet press with main compression force 10–22 kN. Compliance for the dry-granulated intermediate is established under ICH Q6A for granule particle-size distribution and USP <711> for dissolution from the final tablets; cleaning validation follows 21 CFR 211.67. The terminal dosage form is an immediate-release tablet or capsule filler, typically 200–600 mg total mass, with hardness 60–120 N and disintegration below 15 minutes in purified water. This dry granulation route minimizes solvent-induced degradation of the dithiooxamide core while retaining acceptable flow for high-speed tableting.

When High-Shear Granulation Is Deployed for Low-Dose Tablet Granules

Above 60% RH, the dithiooxamide core exhibits hydrolytic sensitivity, so high-shear wet granulation is reserved for low-dose formulations that cannot meet content uniformity by direct compression. Primary amine-containing binders and strongly alkaline granulating fluids are excluded because thioamide moieties undergo nucleophilic attack under those conditions. A vertical high-shear granulator with a 600 L bowl, impeller speed 150–250 rpm, and chopper speed 1500–3000 rpm is used; the granulating fluid is purified water or a 2–5% w/w povidone K30 solution added at 8–12% w/w over 3–6 minutes. The active is premixed with lactose monohydrate 200 Mesh and maize starch in a ratio of 0.5% w/w to 10.0% w/w of active, followed by wet massing until torque reaches 30–50 N·m on the granulator impeller. Drying is completed in a Glatt WSG 120 fluid bed dryer with inlet air temperature 55–70 °C, product temperature 30–40 °C, and final loss on drying 1.5–3.0% measured by USP <731>. The dried granules are milled using a Comil U20 with 813 µm screen and round impeller at 1500 rpm; the granule fraction between 125 µm and 850 µm is retained for the final blend. Lubrication with 0.5% w/w magnesium stearate is limited to 3 minutes at 12 rpm. Finished tablets or capsules are released against USP <2040> disintegration, USP <711> dissolution, and ICH Q3D elemental impurity thresholds. The terminal product is either a low-dose immediate-release tablet or a granule-filled capsule; the same granulate may be filled into sachets if protected from moisture by aluminum foil laminate packaging because the dithiooxamide core is sensitive to hydrolytic ring-opening at elevated humidity above 60% RH.

Sterile injectable presentations require solubility-enhancing vehicles because the two dodecyl chains produce negligible aqueous solubility and a high octanol-water partition coefficient; published data for this specific configuration is limited, and formulation screening must follow a design-of-experiments matrix according to ICH Q8(R2). The active is dissolved in a non-aqueous vehicle composed of PEG 400 and propylene glycol with 10–30% v/v ethanol or in a pH-adjusted aqueous solution containing 20–40% w/v sulfobutylether-β-cyclodextrin if parenteral isotonicity permits. The final active concentration for injectable solution is established by solubility screening; typical platform concentrations for lipophilic dithiooxamide analogs range from 0.1 mg/mL to 5.0 mg/mL, but higher loading has not been documented in public compendial monographs. The solution is compounded in a Grade D preparation area and sterilized by filtration through two 0.22 µm polyvinylidene fluoride membrane filters in series, followed by aseptic filling in a Grade A environment under unidirectional airflow according to EU GMP Annex 1 and ISO 14644-1 Class 5. Sterility testing follows USP <71>, bacterial endotoxins testing follows USP <85>, particulate matter testing follows USP <788>, and container closure integrity testing follows USP <1207>. The terminal product type is a sterile solution in Type I glass vials or ampoules with nitrogen headspace flushing; terminal sterilization is avoided because the dithiooxamide core can undergo thermal degradation above 121 °C sustained for 15 minutes if the solution is not buffered.

Lyophilizing Sterile Vials for Reconstitution: Cycle Design and Cake Collapse Limits

Because the active is poorly soluble and oxidation-prone in aqueous solution, freeze-drying is selected for injectable products that require a longer shelf life than a ready-to-use solution. A lyophilization formulation is prepared by dissolving the active in a solvent system of 20–30% v/v tert-butanol and water with trehalose dihydrate 2–5% w/v and mannitol 1–3% w/v as cryoprotectants and bulking agents. The active concentration in the lyophilization fill solution is validated between 0.5 mg/mL and 2.0 mg/mL; higher concentrations often result in cake collapse because the lipophilic active precipitates during freezing and disrupts the ice crystal network. The fill volume is 2.0 mL or 5.0 mL in Type I tubing glass vials with bromobutyl stoppers. The freeze-drying cycle uses a Lyostar 3 or equivalent with shelf temperature ramped from −50 °C to −40 °C for annealing at −20 °C for 2 hours, primary drying at −25 °C shelf with chamber pressure 80–150 mTorr for 24–48 hours, and secondary drying at 40 °C for 6–10 hours. The critical collapse temperature is assessed by freeze-drying microscopy and should remain above −28 °C for the chosen formulation. Process compliance includes USP <921> water determination with acceptance below 3.0%, USP <1207> container closure integrity, USP <71> sterility, and USP <85> bacterial endotoxins. Terminal product is a sterile lyophilized cake for reconstitution with sterile water or 0.9% sodium chloride injection to a final active concentration prior to intravenous infusion or intramuscular injection; the reconstituted solution must be used within 6 hours at 2–8 °C unless otherwise justified by stability data.